Arsenal Capital Buys Cyalume for $45 million

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

New York-based private equity group Arsenal Capital Partners has signed a definitive agreement to acquire Cyalume Technologies Holdings for $45 million in cash.

Headquartered in Fort Lauderdale, Florida, USA, Cyalume is a producer of specialty chemicals, active pharmaceutical intermediates (APIs), complex long chain polymers and chemical light products. The company also performs sub-contract manufacturing of products used in pharmaceutical, medical, commercial and military markets. It has manufacturing plants in West Springfield, Massachusetts and Bound Brook, New Jersey in the US as well as a subsidiary in Aix-en-Provence in France.

Cyalume’s chief operating officer, Dale Baker, said that with Arsenal’s strategic and financial support, the company will be able to significantly accelerate its growth in the specialty chemical, pharmaceutical and medical product markets.

“Given its robust portfolio of technologies, we expect that Cyalume will serve as a platform for further acquisitions in the specialty chemicals and performance polymers sector,” added Sal Gagliardo, industry and operations partner at Arsenal.

The deal is expected to close in September, subject to satisfying certain closing conditions. The acquisition has the approval of Cyalume’s board of directors as well as the necessary endorsement from stockholders.  Cyalume’s management team will remain in place once the transaction has completed.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.